If this message does not display properly, please click here to launch your browser.
| Revlimid Continues to Show Promise as a Maintenance Treatment in Multiple Myeloma – News from ASCO Based on our Pharmacor advisory service entitled Multiple Myeloma, Decision Resources is offering an exclusive analyst call entitled Revlimid Continues to Show Promise as a Maintenance Treatment in Multiple Myeloma – News from ASCO. Because this presentation will feature updates to the Multiple Myeloma topic, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. Clinical trial data presented earlier this month at the 2010 American Society of Clinical Oncology (ASCO) general meeting continued to highlight the potential role of Celgene’s Revlimid as a maintenance treatment for multiple myeloma. Revlimid is currently well entrenched in current clinical practice for relapsed/refractory multiple myeloma patients, but has considerable clinical and commercial potential if uptake can be extended into the maintenance setting. Other developments announced at ASCO included the release of encouraging and significant overall survival data for the highly prescribed bisphosphonate, zoledronic acid (Novartis’ Zometa), in the first-line treatment of multiple myeloma. This 15-minute analyst call, presented by Analyst Andrew Merron, Ph.D., will answer the following questions:
Dr. Merron will conduct a live Q & A session after the presentation. Registration Revlimid Continues to Show Promise as a Maintenance Treatment in Multiple Myeloma – News from ASCO June 25, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Andrew Merron, Ph.D., is a senior oncology analyst at Decision Resources. Dr Merron’s research interests and areas of expertise cover hematological malignancies (including lymphoma, leukemia and myeloma) and prostate cancer. Dr. Merron received his Ph.D. in molecular oncology from the University of London. His doctorate focused on in vivo molecular imaging of cancer gene therapies, specifically oncolytic adenoviruses. Prior to obtaining his Ph.D., he earned his B.Sc. in biochemistry from the University of Bath.